Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2015
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancerJ O'Shaughnessy, M Campone, E Brain, et al.
European Journal of Cancer Care|November 22, 2014
Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and BelgiumG W J Frederix, J L Severens, A M Hövels, et al.
Breast Cancer Research and Treatment|November 22, 2017
Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional studyO Brouckaert, K Van Asten, A Laenen, et al.
Breast Cancer Research and Treatment|August 30, 2014
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxelC Vulsteke, A M Pfeil, M Schwenkglenks, et al.
Breast Cancer Research and Treatment|May 13, 2011
Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patientsT Vandorpe, A Smeets, B Van Calster, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trialsF André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trialsF André, N Solovieff, F Su, et al.
Breast Cancer Research and Treatment|February 11, 2018
Breast cancer subtype and survival by parity and time since last birthH De Mulder, A Laenen, H Wildiers, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2015
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancerJ O'Shaughnessy, M Campone, E Brain, et al.
European Journal of Cancer Care|November 22, 2014
Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and BelgiumG W J Frederix, J L Severens, A M Hövels, et al.
Breast Cancer Research and Treatment|November 22, 2017
Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional studyO Brouckaert, K Van Asten, A Laenen, et al.
Breast Cancer Research and Treatment|August 30, 2014
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxelC Vulsteke, A M Pfeil, M Schwenkglenks, et al.
Breast Cancer Research and Treatment|May 13, 2011
Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patientsT Vandorpe, A Smeets, B Van Calster, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trialsF André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trialsF André, N Solovieff, F Su, et al.
Breast Cancer Research and Treatment|February 11, 2018
Breast cancer subtype and survival by parity and time since last birthH De Mulder, A Laenen, H Wildiers, et al.
Pageof 14